AFT Pharmaceuticals Ltd  (“AFT”) has partnered with Accelera Pharma Canada Inc. (“APCI”) as its exclusive importer and distributor of COMBOGESIC® IV in Canada.

INDICATIONS

COMBOGESIC IV (Acetaminophen/Ibuprofen Solution for intravenous Infusion ) is indicated for the short term management of:

• mild to moderate pain
• moderate to severe pain as an adjunct to opioid analgesics

and  where an intravenous route of administration is considered clinically necessary and/or when other routes of administration are not possible.

• Pediatrics

Pediatrics (< 18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

• Geriatrics

 Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see Product Monograph: Warnings  and Precautions – Special Populations – Geriatrics).

For further information about the product, including the Product Monograph  please refer to the link below:

COMBOGESIC IV PRODUCT MONOGRAPH

Details of the Product codes are as follows:

Please contact the Accelera Pharma Canada Inc. (“APCI”) Customer Service Team to place your order at:

Toll Free: 1-855-611-2724 Ext 2202
e-FAX: 647-660-0279
Email: orders@apcipharma.com

For adverse events or product complaints, please call 1-855-611-2724

pharmaand GmbH (“pharma&”) has partnered with Accelera Pharma Canada Inc. (“APCI”) as its exclusive distributor of PEGASYS® in Canada.

DESCRIPTION  OF PEGASYS:

Peginterferon alfa-2a is a covalent conjugate of recombinant alfa-2a interferon (approximate molecular weight [MW] 20 kD) with a single branched bis-monomethoxy polyethylene glycol (PEG) chain (approximate MW 40 kD). Interferon alfa-2a is produced biosynthetically using recombinant DNA technology, and is the product of a cloned human leukocyte interferon gene inserted into and expressed in E. coli.

INDICATIONS AND CLINICAL USE 

Chronic Hepatitis C (CHC)

PEGASYS (peginterferon alfa-2a) is indicated for the treatment of Chronic Hepatitis C in:

• Adult patients without cirrhosis
• Adult patients with compensated cirrhosis,

including HCV/HIV co-infection patients with stable HIV disease with or without antiretroviral therapy.

Chronic Hepatitis B (CHB)

PEGASYS is indicated for the treatment of both HBeAg-positive and HBeAg-negative chronic hepatitis B in:

• Patients with compensated liver disease, liver inflammation and evidence of viral          replication (both cirrhotic and non-cirrhotic disease).

Geriatrics (> 65 years of age): Clinical studies of PEGASYS alone or in combination with COPEGUS did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects.

Pediatrics (< 18 years of age): PEGASYS is not authorized for use in children and adolescents under the age of 18 years (see WARNINGS AND PRECAUTIONS: Special Populations, Pediatrics).

Details of the Product codes are as follows:

PEGASYS® PFS 180 mcg/0.5 mL

Please contact the Accelera Pharma Canada Inc. (“APCI”) Customer Service Team to place your order at:

Toll Free: 1-855-611-2724 Ext 2202
e-FAX: 647-660-0279
Email: orders@apcipharma.com
For adverse events or product complaints, please call 1-855-611-2724

Cold chain products cannot be ordered with ambient product when placing orders with APCI.

Details of the Product codes are as follows:

PEGASYS® PFS 180 mcg/0.5 mL

Please contact the Accelera Pharma Canada Inc. (“APCI”) Customer Service Team to place your order at:

Toll Free: 1-855-611-2724 Ext 2202
e-FAX: 647-660-0279
Email: orders@apcipharma.com
For adverse events or product complaints, please call 1-855-611-2724

Cold chain products cannot be ordered with ambient product when placing orders with APCI.

VIOKACE™ is used for the treatment of exocrine pancreatic insufficiency (EPI) attributed to cystic fibrosis, chronic pancreatitis, or any other medically defined pancreatic disease that might require pancreatic enzyme therapy.

 Details of the Product codes are as follows:

Please contact the Accelera Pharma Canada Inc. (“APCI”) Customer Service Team to place your order at:

Toll Free: 1-855-611-2724 Ext 2202
e-FAX: 647-660-0279
Email: orders@apcipharma.com

Details of the Product codes are as follows:

Please contact the Accelera Pharma Canada Inc. (“APCI”) Customer Service Team to place your order at:

Toll Free: 1-855-611-2724 Ext 2202
e-FAX: 647-660-0279
Email: orders@apcipharma.com

Accelera Pharma Canada Inc. (APCI), in partnership with Halewood Chemicals Ltd., is pleased to announce HALYCIL ^TM (propylthiouracil 50mg Tablets) 56 tablets in Blister Pack format approved by Health Canada is now available.

HALYCIL ^TM is indicated for Adults (≥18 years of age):

• For the medical management of hyperthyroidism.
• In conjunction with radioiodine to hasten recovery while awaiting the effects of radiation.
• For the control of thyrotoxicosis prior to surgery.
• In the management of a thyroid storm in addition to other therapeutic measures.

The DIN number is:  02521059

The recommended dose and dose adjustment is as follows:

Adults (≥18 years of age): The recommended initial dose is 50-100 mg (1 to 2 tablets of HALYCIL) every 8 hours, with increases as necessary up to a maximum of 500 mg/day.
In some cases, initial doses as high as 900 mg/day may be required.

When doses larger than 300 mg/day of HALYCIL are needed, the drug should be administered every 4 to 6 hours.The patient should be examined regularly by the physician and the dose of HALYCIL adjusted until the patient is euthyroid (usually after 6-8 weeks). At this stage, the dose should be reduced by 1/3 every 4-6 weeks to a maintenance dosage of one tablet of HALYCIL 2 or 3 times daily, administered at regular intervals.

Geriatric (65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with no differences in safety or effectiveness. Dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Pediatric (18 years of age): Health Canada has not authorized an indication for pediatric use.

Hepatic impairment: No clinical studies have been performed with HALYCIL in patients with hepatic insufficiency. Since liver toxicity is associated with the use of propylthiouracil, caution is warranted in these patients. The dose should be kept as low as possible.

 Renal impairment: No clinical studies have been performed with HALYCIL in patients with renal impairment. The following schedule is recommended by W.M. Bennett et al^[1]:

HALYCIL™ is available in Blister Packs of 50mg tablets containing 56 tablets per pack.

Bennett WM et al. Guidelines for drug therapy in renal failure. Ann Intern Med 1977; 86:754-83.

* HALYCIL™ (propylthiouracil 50mg Tablets) 56 tablets in Blister Pack format, will replace the UK product, Propylthiouracil (PTU) 50 mg Tablets manufactured by Halewood Chemicals (previously available under an interim order) and no longer available.   Prescriptions for HALYCIL™ (propylthiouracil 50mg Tablets), should be written as “ HALYCIL™ (propylthiouracil 50mg Tablets)”, to ensure patients receive the prescribed branded product.

For further information about the product, including the product monograph please refer to the link below:

Please contact the Accelera Pharma Canada Inc. (“APCI”) Customer Service Team to place your order at:

Toll Free: 1-855-611-2724 Ext 2202
e-FAX: 647-660-0279 H
Email: orders@apcipharma.com

For adverse events or product complaints, please call 1-855-611-2724

Accelera Pharma Canada Inc. (APCI), in partnership with Halewood Chemicals Ltd., is pleased to announce HALYCIL ^TM (propylthiouracil 50mg Tablets) 100 tablets in Blister Pack format approved by Health Canada is now available.

HALYCIL ^TM is indicated for Adults (≥18 years of age):

• For the medical management of hyperthyroidism.
• In conjunction with radioiodine to hasten recovery while awaiting the effects of radiation.
• For the control of thyrotoxicosis prior to surgery.
• In the management of a thyroid storm in addition to other therapeutic measures.

The DIN number is:  02521059

The recommended dose and dose adjustment is as follows:

Adults (≥18 years of age): The recommended initial dose is 50-100 mg (1 to 2 tablets of HALYCIL) every 8 hours, with increases as necessary up to a maximum of 500 mg/day.
In some cases, initial doses as high as 900 mg/day may be required.

When doses larger than 300 mg/day of HALYCIL are needed, the drug should be administered every 4 to 6 hours.The patient should be examined regularly by the physician and the dose of HALYCIL adjusted until the patient is euthyroid (usually after 6-8 weeks). At this stage, the dose should be reduced by 1/3 every 4-6 weeks to a maintenance dosage of one tablet of HALYCIL 2 or 3 times daily, administered at regular intervals.

Geriatric (65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with no differences in safety or effectiveness. Dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Pediatric (18 years of age): Health Canada has not authorized an indication for pediatric use.

Hepatic impairment: No clinical studies have been performed with HALYCIL in patients with hepatic insufficiency. Since liver toxicity is associated with the use of propylthiouracil, caution is warranted in these patients. The dose should be kept as low as possible.

 Renal impairment: No clinical studies have been performed with HALYCIL in patients with renal impairment. The following schedule is recommended by W.M. Bennett et al^[1]:

HALYCIL™ is available in Blister Packs of 50mg tablets containing 56 or 100 tablets per pack.

Bennett WM et al. Guidelines for drug therapy in renal failure. Ann Intern Med 1977; 86:754-83.

* HALYCIL™ (propylthiouracil 50mg Tablets) 100 tablets in Blister Pack format, will replace the UK product, Propylthiouracil (PTU) 50 mg Tablets manufactured by Halewood Chemicals (previously available under an interim order) and no longer available.   Prescriptions for HALYCIL™ (propylthiouracil 50mg Tablets), should be written as “ HALYCIL™ (propylthiouracil 50mg Tablets)”, to ensure patients receive the prescribed branded product.

For further information about the product, including the product monograph please refer to the link below:

Please contact the Accelera Pharma Canada Inc. (“APCI”) Customer Service Team to place your order at:

Toll Free: 1-855-611-2724 Ext 2202
e-FAX: 647-660-0279 H
Email: orders@apcipharma.com

For adverse events or product complaints, please call 1-855-611-2724